• News
  • SAN DIEGO
  • BioTech

Mast Therapeutics begins phase 2 study of MST-188

San Diego's Mast Therapeutics Inc. (NYSE: MSTX) has initiated a phase 2, clinical proof-of-concept study of MST-188 in combination with recombinant tissue plasminogen activator (rt-PA) in patients with acute lower limb ischemia (ALI).

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Mast Therapeutics Inc.

Company Website

12390 El Camino Real Ste., 150
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
MSTX
0.62
  0.02  
+ 3.33%
531,283,000
1.10
0.40

Mast Therapeutics Inc. Executive(s):

Brian Culley

  • Chief Executive Officer

Patrick Keran

  • Chief Operating Officer, President

Brandi Roberts

  • Chief Financial Officer
Subscribe Today!